Differential effects of age on human striatal adenosine A1 and A2A receptors

Synapse

Volumn 66, Issue 9, 2012, Pages 832-839

  Mishina, Masahiro ^a,b   Kimura, Yuichi ^b,c   Naganawa, Mika ^d   Ishii, Kenji ^b   Oda, Keiichi ^b   Sakata, Muneyuki ^b   Toyohara, Jun ^b   Kobayashi, Shiro ^e   Katayama, Yasuo ^a   Ishiwata, Kiichi ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^d YALE UNIVERSITY   (United States)

^e NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Adenosine A1 receptor; Adenosine A2A receptor; Positron emission tomography

Indexed keywords

7 METHYL 8 (3,4,5 TRIMETHOXYSTYRYL) 1,3,7 TRIMETHYLXANTHINE C 11; 8 DICYCLOPROPYLMETHYL 1 METHYL 3 PROPYLXANTHINE C 11; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CAUDATE NUCLEUS; CORPUS STRIATUM; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL INSTRUMENTATION; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; VOLUNTEER;

ADULT; AGE FACTORS; AGED; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; XANTHINES;

EID: 84863476384     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21573     Document Type: Article

References (93)

1. Abe K, Saito H. 1998. Adenosine stimulates stellation of cultured rat cortical astrocytes. Brain Res 804: 63-71.
2. Addicott MA, Yang LL, Peiffer AM, Burnett LR, Burdette JH, Chen MY, Hayasaka S, Kraft RA, Maldjian JA, Laurienti PJ. 2009. The effect of daily caffeine use on cerebral blood flow: How much caffeine can we tolerate? Human Brain Mapp 30: 3102-3114.
3. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC. 2001. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50: 56-63.
4. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. 2003. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60: 790-795.
5. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. 2000. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: A case-control study. Neurology 55: 1350-1358.
6. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. 1999. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: A crossover study. Neurology 53: 91-95.
7. 2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43: 190-194.
8. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127: 1075-1084.
9. Ciccarelli R, Di Iorio P, Ballerini P, Ambrosini G, Giuliani P, Tiboni GM, Caciagli F. 1994. Effects of exogenous ATP and related analogues on the proliferation rate of dissociated primary cultures of rat astrocytes. J Neurosci Res 39: 556-566.
10. Colrain IM. 2011. Sleep and the brain. Neuropsychol Rev 21: 1-4.
11. 2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr 86: 240-244.
12. 1 sites. Neurosci 28: 263-273.
13. 2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport 6: 1583-1588.
14. 1 receptor binding sites in the rat brain. Effect of cis unsaturated free fatty acids. Eur J Biochem 268: 2939-2947.
15. Daré E, Schulte G, Karovic O, Hammarberg C, Fredholm BB. 2007. Modulation of glial cell functions by adenosine receptors. Physiol Behav 92(1-2): 15-20.
16. De Keyser J, Ebinger G, Vauquelin G. 1990. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 27: 157-161.
17. de Paula Cognato G, Bruno AN, Vuaden FC, Sarkis JJ, Bonan CD. 2005. Ontogenetic profile of ectonucleotidase activities from brain synaptosomes of pilocarpine-treated rats. Int J Dev Neurosci Official J Int Soc Dev Neurosci 23: 703-709.
18. Dijk DJ, Duffy JF, Czeisler CA. 2000. Contribution of circadian physiology and sleep homeostasis to age-related changes in human sleep. Chronobiol Int 17: 285-311.
19. Dunwiddie TV, Masino SA. 2001. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24: 31-55.
20. 1 adenosine receptor binding in the human brain: A positron emission tomography study. J Neurosci 27: 2410-2415.
21. Fall PA, Fredrikson M, Axelson O, Granerus AK. 1999. Nutritional and occupational factors influencing the risk of Parkinson's disease: A case-control study in southeastern Sweden. Mov Disord 14: 28-37.
22. 2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88: 7238-7241.
23. 1 receptors. Neuroreport 6: 73-76.
24. 2A-receptors. Glia 18: 152-160.
25. Field AS, Laurienti PJ, Yen YF, Burdette JH, Moody DM. 2003. Dietary caffeine consumption and withdrawal: Confounding variables in quantitative cerebral perfusion studies? Radiology 227: 129-135.
26. Fredholm BB, Svenningsson P. 2003. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology 61( Suppl): S5-S9.
27. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83-133.
28. Fredholm BB, Jacobson KA, Klotz KN, Linden J. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
29. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, Ishii K, Orihara H, Fukuda H, Satoh T, Kitamura K, Tanaka K, Takahashi S. 1997. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. Ann Nucl Med 11: 307-313.
30. 11C-methyl-3-propylxanthine. J Nucl Med 46: 32-37.
31. 2-receptors are required to stimulate microglial proliferation. Neurochem Int 29: 37-42.
32. Glass M, Faull RL, Bullock JY, Jansen K, Mee EW, Walker EB, Synek BJ, Dragunow M. 1996. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res 710(1-2): 56-68.
33. 1 adenosine receptor-adenylate cyclase system in rat cerebral cortex. J Clin Invest 77: 222-227.
34. Hellenbrand W, Seidler A, Robra BP, Vieregge P, Oertel WH, Joerg J, Nischan P, Schneider E, Ulm G. 1997. Smoking and Parkinson's disease: a case-control study in Germany. Int J Epidemiol 26: 328-339.
35. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431: 331-346.
36. 2 receptor agonist. J Neurosci Res 38: 399-406.
37. 2-like receptors in human striatum. Synapse 63: 282-290.
38. 2A antagonist. Appl Radiat Isot 47(5-6): 507-511.
39. 2A receptor ligand. J Nucl Med 41: 345-354.
40. 11C]KF18446 with in vitro autoradiography and in vivo tissue uptake. Ann Nucl Med 14: 81-89.
41. 11C]KF18446 PET in the rat brain after quinolinic acid lesion: Comparison with the dopamine receptor imaging. Ann Nucl Med 16: 467-475.
42. 2A receptors by positron emission tomography. Ann Nucl Med 17: 205-211.
43. 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 15: 406-413.
44. Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. 1992. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: A case-control study. Mov Disord 7: 339-344.
45. 1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat. Psychopharmacol 201: 529-539.
46. 11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine. Nucl Med Biol 31: 975-981.
47. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. 2002. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 58: 1418-1422.
48. Kovács Z, Juhasz G, Dobolyi A, Bobest M, Papp V, Takats L, Kekesi KA. 2010. Gender- and age-dependent changes in nucleoside levels in the cerebral cortex and white matter of the human brain. Brain Res Bull 81: 579-584.
49. 3H]spiperone binding sites in striatum. Neurochem Int 20: 559-566.
50. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I. 2006. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: The Ohsaki study. JAMA 296: 1255-1265.
51. Latini S, Pedata F. 2001. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79: 463-484.
52. Li W, Dai S, An J, Li P, Chen X, Xiong R, Liu P, Wang H, Zhao Y, Zhu M, Liu X, Zhu P, Chen JF, Zhou Y. 2008. Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Neurosci 151: 1198-1207.
53. 2A adenosine receptors. Life Sci 68: 1343-1350.
54. Logan J. 2003. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol 30: 833-844.
55. 2A receptors in the limbic cortex, but not striatum, of aged rats. J Neurochem 73: 1733-1738.
56. Lu H, Chen C, Klaassen C. 2004. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug metabolism and disposition: The biological fate of chemicals 32: 1455-1461.
57. McNeill TH, Brown SA, Rafols JA, Shoulson I. 1988. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res 455: 148-152.
58. 1 receptor binding in the rat brain: An autoradiographic study. J Neurosci Res 78: 742-748.
59. 2 receptors in human basal ganglia. Brain Res 843(1-2): 136-144.
60. 18F]CPFPX PET study in humans. Neurobiol Aging 28: 1914-1924.
61. 11C]flumazenil PET. Ann Nucl Med 14: 193-198.
62. 11C]TMSX PET in the striata of Parkinson's disease patients. PLoS One 6: e17338.
63. 11C]TMSX PET. Synapse 61: 778-784.
64. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. 2010. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study. Mov Disord 25: 1437-1443.
65. Morgan DG, Marcusson JO, Nyberg P, Wester P, Winblad B, Gordon MN, Finch CE. 1987. Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging. Neurobiol Aging 8: 195-201.
66. 2A antagonists. Neurology 61( Suppl): S44-S48.
67. Nagayama H, Ueda M, Kumagai T, Tsukamoto K, Nishiyama Y, Nishimura S, Hamamoto M, Katayama Y. 2011. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease. Parkinsonism Relat Disord 17: 150-152.
68. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. 2004. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: Developing normative sleep values across the human lifespan. Sleep 27: 1255-1273.
69. 1 receptors and promotes non-rapid eye movement sleep. Proc Natl Acad Sci USA 105: 19992-19997.
70. 2A receptors in the rat dorsomedial nucleus of the solitary tract at the level of the area postrema. Synapse 60: 496-509.
71. 1 agonists in dopamine-denervated rats. Eur J Neurosci 8: 1176-1181.
72. Popoli P, Betto P, Rimondini R, Reggio R, Pezzola A, Ricciarello G, Fuxe K, Ferre S. 1998. Age-related alteration of the adenosine/dopamine balance in the rat striatum. Brain Res 795(1-2): 297-300.
73. 2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. JNeurochem 88: 1151-1158.
74. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. 2011. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76: 1811-1816.
75. 2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J Neurophysiol 90: 1295-1303.
76. Reeves S, Bench C, Howard R. 2002. Ageing and the nigrostriatal dopaminergic system. Int J Geriatr Psychiatry 17: 359-370.
77. 2 receptors. Brain Res 508: 349-352.
78. 2A receptors in brain: morphological substrates for integration of striatal function. Neurology 61( Suppl 6): S12-S18.
79. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283: 2674-2679.
80. Rucker B, Pereira GS, Furstenau CR, Izquierdo I, Bonan CD, Sarkis JJ. 2004. Inhibitory avoidance task reveals differences in ectonucleotidase activities between male and female rats. Neurochem Res 29: 2231-2237.
81. 2A agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neurosci 107: 653-663.
82. Schiffmann SN, Vanderhaeghen JJ. 1993. Age-related loss of mRNA encoding adenosine A2 receptor in the rat striatum. Neuroscience letters 158: 121-124.
83. 2A receptors in Parkinson's disease. Trends in neurosciences 29: 647-654.
84. Shah RH, Frishman WH. 2009. Adenosine1 receptor antagonism: A new therapeutic approach for the treatment of decompensated heart failure. Cardiol Rev 17: 125-131.
85. Statland BE, Demas TJ. 1980. Serum caffeine half-lives. Healthy subjects vs. patients having alcoholic hepatic disease. Am J Clin Pathol 73: 390-393.
86. 1 dopamine receptors measured by positron emission tomography. Psychopharmacol 103: 41-45.
87. Ulas J, Brunner LC, Nguyen L, Cotman CW. 1993. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: A quantitative autoradiographic study. Neurosci 52: 843-854.
88. 2A receptor-deficient mice. Neurology 61( Suppl 6): S94-S96.
89. Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, Apte UM, Wiley CA. 2009. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging 30: 1217-1226.
90. 1 receptors in human brain: A PET study. Synapse 30: 56-61.
91. 2A receptor signaling in the neostriatum. Neurosci 141: 19-25.
92. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ. 2005. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64: 545-547.
93. Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Ciro-Candiano IC, Gambardella A, Quattrone A. 2005. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study. Arch Neurol 62: 601-605.